Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non-ischemic Cardiomyopathy Clear all
Completed No phase listed Observational Accepts healthy volunteers

Surpoint Algorithm for Improved Guidance of Ablation for Ventricular Tachycardia

NCT05618717
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Radiofrequency Ablation
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
19 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

NCT03884608
View directory record Official record
Conditions
Cardiomyopathies, Gender, Implantable Defibrillator User
Interventions
Not listed
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Fairhope, Alabama • Rancho Mirage, California + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

NCT01020968
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Ixmyelocel-T, Vehicle Control
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
18 Years to 86 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Cleveland, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy

NCT01935622
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Interventions
Doxycycline, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

NCT00765518
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Ixmyelocel-T, Standard of Care
Biological · Other
Lead sponsor
Vericel Corporation
Industry
Eligibility
18 Years to 86 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Atlanta, Georgia • Cleveland, Ohio • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Phase 2 Interventional

Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure

NCT05598333
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
AB-1002
Drug
Lead sponsor
AskBio Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

NCT00665301
View directory record Official record
Conditions
Congestive Heart Failure, Ischemic Cardiomyopathy, Mitral Valve Prolapse, Mitral Regurgitation, Aortic Valve Disease, Tricuspid Regurgitation
Interventions
Not listed
Lead sponsor
Woolsthorpe Technologies, LLC
Industry
Eligibility
18 Years to 95 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2008 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

NCT01392625
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
Autologous hMSCs, Allogeneic hMSCs
Biological
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 95 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG

NCT01432626
View directory record Official record
Conditions
Stress Induced Cardiomyopathy
Interventions
I-123 radiolabeled metaiodobenzylguanidine cardiac imaging
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Jul 22, 2026, 8:30 AM EDT
Not listed Phase 2Phase 3 Interventional

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

NCT00691470
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction, Cardiomyopathy
Interventions
ATI-5923, Coumadin (warfarin)
Drug
Lead sponsor
ARYx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance

NCT03509441
View directory record Official record
Conditions
Cardiomyopathies, Insulin Resistance, Non-ischemic Cardiomyopathy, Cardiac Fibrosis, Diabetes
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

DNA/RNA Analysis of Blood and Skeletal Muscle in Patients Undergoing Cardiac Resynchronization Therapy (CRT)

NCT00600392
View directory record Official record
Conditions
Cardiomyopathy (Ischemic or Non-Ischemic)
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2016 · Synced Jul 22, 2026, 8:30 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of the Acute Effects of Triheptanoin in Heart Failure

NCT01787851
View directory record Official record
Conditions
Congestive Heart Failure, Non-ischemic Cardiomyopathy
Interventions
Triheptanoin oil
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Jul 22, 2026, 8:30 AM EDT
Not listed No phase listed Observational

SCD-HeFT 10 Year Follow-up

NCT01058837
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions
Not listed
Lead sponsor
Seattle Institute for Cardiac Research
Other
Eligibility
18 Years to 90 Years
Enrollment
1,855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Not applicable Interventional Results available

Immunoadsorption Therapy for Patients With Non-Ischemic Dilated Cardiomyopathy (DCM)

NCT01478087
View directory record Official record
Conditions
Cardiomyopathy, Dilated
Interventions
Mysorba
Device
Lead sponsor
Asahi Kasei Medical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jul 22, 2026, 8:30 AM EDT
Terminated Phase 2 Interventional Results available

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

NCT03925324
View directory record Official record
Conditions
Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Interventions
Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Placebo
Biological · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Cardiovascular Multimodality Imaging Study

NCT06610019
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Phase 2 Interventional

A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

NCT01643330
View directory record Official record
Conditions
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
Interventions
AAV1/SERCA2a (MYDICAR), Placebo
Genetic
Lead sponsor
Celladon Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jul 22, 2026, 8:30 AM EDT
Enrolling by invitation Phase 4 Interventional

Comparing Immune System Suppression to Medication for Unexplained Heart Function and Irregular Heartbeat

NCT06635863
View directory record Official record
Conditions
Ventricular Arrythmia, Non-ischemic Cardiomyopathy, Arrhythmogenic Inflammatory Cardiomyopathy
Interventions
Prednisone 40mg
Drug
Lead sponsor
Roderick Tung
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jul 22, 2026, 8:30 AM EDT
Completed Not applicable Interventional Results available

CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients

NCT01983293
View directory record Official record
Conditions
Non-left Bundle Branch Block, Ischemic or Non-ischemic Cardiomyopathy
Interventions
QLV based implant strategy, Standard of care implant strategy
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
32
States / cities
Glendale, California • Los Angeles, California • Mission Viejo, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Jul 22, 2026, 8:30 AM EDT
Recruiting No phase listed Observational

Phenotypic Classification of FMR With CMR

NCT05965258
View directory record Official record
Conditions
Nonischemic Congestive Cardiomyopathy, Functional Mitral Regurgitation, Ischemic Cardiomyopathy
Interventions
Cardiac magnetic resonance (CMR)
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 22, 2026, 8:30 AM EDT
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 8:30 AM EDT
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 22, 2026, 8:30 AM EDT